EUVIMEDEUVIMED entdecken
Vergleichsstudie

Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer

Mike Wenzel, Florestan Koll, Benedikt Hoeh, Clara Humke, Carolin Siech, Nicolai Mader, Amir Sabet, Daniel Groener, Thomas Steuber, Markus Graefen, Tobias Maurer, Christian Brandts und 3 weitere

Journal of Nuclear Medicine · 2025-01 · 66 (1) · 61-66

DOI: 10.2967/jnumed.124.268807 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 14.11.2024. Verfasst von Mike Wenzel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany; mike.wenzel@unimedizin-ffm.de. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Lutetium, Radiopharmaceuticals, Taxoids. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

177Lu-vipivotide tetraxetan prostate-specific membrane antigen (177Lu-PSMA) therapy is under current scientific investigation and aims to become established in the treatment of metastatic castration-resistant prostate cancer (mCRPC). However, real-world evidence in treatment comparison is scant.

Methods

We relied on the FRAMCAP database and compared cabazitaxel versus 177Lu-PSMA therapy in mCRPC patients regarding progression-free survival (PFS) and overall survival (OS). Sensitivity analyses addressed second- to fourth-line mCRPC treatment to approximate current phase III patient selection criteria.

Results

Of 373 patients, 14% received cabazitaxel, 65% received 177Lu-PSMA, and 21% received both. Patients undergoing 177Lu-PSMA therapy were significantly older than cabazitaxel patients (median, 72 y vs. 66 y; P < 0.01), and a higher proportion had an Eastern Cooperative Oncology Group score of 2 or more (12% vs. 5.0%, P = 0.1). Rates of a prostate-specific antigen decline of at least 50% were 32% versus 0% for 177Lu-PSMA versus cabazitaxel. In outcome analyses, significant superior median PFS was observed for 177Lu-PSMA versus cabazitaxel (13.4 mo vs. 7.1 mo, P < 0.001), even after multivariable adjustment (hazard ratio, 0.38; P < 0.001). Regarding OS, rates also significantly differed, with median OS of 14.7 mo versus 16.5 mo versus 29.6 mo for cabazitaxel versus 177Lu-PSMA versus both treatments (P < 0.01). In sensitivity analyses of second- to fourth-line mCRPC treatment, PFS rates and median OS rates for cabazitaxel versus 177Lu-PSMA versus both therapies qualitatively remained the same as for the entire cohort.

Conclusion

In a real-world setting, 177Lu-PSMA provides significantly better PFS and qualitatively better OS rates than does cabazitaxel chemotherapy and should therefore be considered a valuable treatment option for advanced mCRPC patients according to the European Medicines Agency approval.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantLutetiumRadiopharmaceuticalsTaxoidsNeoplasm MetastasisHumansMaleAgedMiddle AgedDipeptidesAged, 80 and overHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Stichwörter der Autor:innen

177LuOSPFSmCRPCsurvival

Substanzen

cabazitaxelLutetiumRadiopharmaceuticalsTaxoidsPluvictoDipeptidesHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany; mike.wenzel@unimedizin-ffm.de.
  • Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Department of Nuclear Medicine, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt, Germany.
  • Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
  • Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany; and.
  • Hematology/Oncology, Department of Medicine, University Hospital Frankfurt, Goethe University, Frankfurt Am Main, Germany.

Zitieren

APA

Wenzel, M., Koll, F., Hoeh, B., Humke, C., Siech, C., Mader, N., Sabet, A., Groener, D., Steuber, T., Graefen, M., Maurer, T., Brandts, C., Banek, S., Chun, F. K. H., & Mandel, P. (2025). Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine, 66(1), 61-66. https://doi.org/10.2967/jnumed.124.268807

Vancouver

Wenzel M, Koll F, Hoeh B, Humke C, Siech C, Mader N, et al. Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer. Journal of Nuclear Medicine. 2025;66(1):61-66. doi:10.2967/jnumed.124.268807

BibTeX
@article{Wenzel2025,
  author = {Wenzel, Mike and Koll, Florestan and Hoeh, Benedikt and Humke, Clara and Siech, Carolin and Mader, Nicolai and Sabet, Amir and Groener, Daniel and Steuber, Thomas and Graefen, Markus and Maurer, Tobias and Brandts, Christian and Banek, Severine and Chun, Felix K H and Mandel, Philipp},
  title = {Real-World Comparison of Cabazitaxel Versus 177 Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer},
  journal = {Journal of Nuclear Medicine},
  year = {2025},
  volume = {66},
  number = {1},
  pages = {61--66},
  doi = {10.2967/jnumed.124.268807}
}
Kostenlos starten →